Health Reform New Deal, The Golden Age of POCT Comes

Medical Network May 28th News In vitro diagnostics is undoubtedly a very hot segment of the medical device industry, of which POCT is the most attention-grabbing and smaller segment.

From Tianfeng Securities analysis, this small area has ushered in a golden era of development.

Graded diagnosis and treatment promote the expansion of grassroots market, POCT first benefit and continue to benefit

Since the process of medical reform can be completed overnight, the industry and the company's development cycle can be seen longer. The first benefit and determination to benefit is the in vitro diagnostics industry.

3. In inquiry medicine, the test is a leading indicator for doctors to make a diagnosis.

Inspection products are divided into highly automated large-scale inspection equipment (such as biochemical, lighting equipment, etc.) and convenient operation, low-cost small-scale inspection equipment (blood cells, POCT). Grass-roots demand from hierarchical diagnosis and treatment, first from small-scale inspection equipment .

In terms of popularity, conventional blood analysis (blood cells) has been popularized at the grassroots level. Conventional proteins and enzymatic tests (biochemicals) have also been decentralized to the grass roots. However, for the immunological tests, the grass roots have not yet reached the level of popularity.

Immune tests include large-scale luminescence and small POCT devices. However, before large-scale luminescence reaches a critical point, considering the cost and detection volume, hospitals will not choose high-throughput immune devices, and manufacturers will not choose such medical treatment. Institutions launch products.

Therefore, it can meet the basic medical needs, simple operation, and small devices that do not require flux become the best solution for the balance of cost and demand.

POCT products will be the first to benefit from this round of medical reforms. We have determined that the dividends for grading diagnosis and treatment policies will bring high-speed development stage to manufacturers for at least 3 years. After 3 years, products will be rich, service reputation will be good, and quality will be the highest quality. enterprise It will gradually increase brand awareness and become a leader.

Zero-sum game between clinical departments and clinical departments, helping to expand POCT usage

POCT is due to its convenience hospital The various clinical departments were tested and used, but currently their accuracy is limited.

In addition, the clinical and laboratory departments have different interest starting points, which leads to limited use in the clinic. However, this limitation is in the process of canceling the proportion of drugs and grading the diagnosis and treatment. The development of the industry is compensated.

In recent years, with the further advancement of medical reform, the total amount of medical insurance has been controlled to prevent doctors from misusing drug Consumables for personal gain aggravated the burden on patients and medical insurance funds, and strictly controlled the total cost of Chinese medicines. Since 2018, the control of the proportion of consumables has also been formally implemented. As a result, the hospital's income cannot be compared with previous large-scale use of medicines and consumables. Become the main source of income.

Under such circumstances, how does the hospital further maintain its own income growth level and seek new sources of incremental income? Currently, it analyzes hospital charging items, and inspection costs are likely to increase in the future and become new revenue increments.

There is no proportion control. Secondly, it is an important basis to support the diagnosis of the doctor. Third, if the examination cost increases, the total cost will increase. The proportion of medicine and the proportion of consumables are fixed. This can also follow. Increase the use of medicines and consumables, so the income of medicines and consumables will also increase.

The POCT product is a new type of portable inspection instrument. It quickly obtains the test results, which is convenient for the patient and reduces the patient's time for diagnosis.

At the same time, POCT products have the function of continuously monitoring the condition of patients, such as heart disease patients, can quickly understand and control the condition through interval testing, which also provides an important way for doctors to increase total cost and increase income.

The POCT price is in the middle level, the price range is between the image detection and the blood routine, and it is within the patient's acceptable range. Therefore, the patient can accept the POCT product as the medium and long-term detection and control instrument.

Therefore, in the current proportion of medicines, under the control of a large proportion of consumables, although not yet implemented in all directions, the trend is irreversible. Future POCT products are likely to become the source of hospitals to provide new incremental income.

The inspection fee is a part of the relatively large proportion of total expenses, and since the hospital has a special laboratory for examination, the examinations of all departments will be collected in the laboratory and the income of all examination fees will be divided into the department and the laboratory for examination. Reduced the total income of each clinical department.

Because POCT is small and convenient, professional skills are not high enough. It is suitable for those who are not specialized in the laboratory work. This is a unilateral monopoly check for clinical departments. It does not have to be subdivided with the laboratory to provide the possibility. Therefore, in the clinical department, With the goal of further income improvement, it is highly probable that the department will introduce POCT products on a large scale in the future.

In January 2018, the former National Health and Family Planning Commission issued the “Notice on Printing and Efforts to Further Improve Medical Services Action Plan (2018-2020)”, clarifying that in eligible prefecture-level cities and counties, qualified medical institutions establish chest pain centers. , Stroke Center, Trauma Center, Critical Maternity Rescue Center, Critical child With the neonatal care center, 5 centers will be constructed in all cities and counties across the country. Each city will build a center.

The common point of the center is that for emergencies such as emergencies, inspections, imaging, and other diagnostic items are mandatory products. Blood test results need to minimize the sample turnaround time (TAT) to achieve the effect of prevention and rescue. Although POCT products Accuracy is limited, but it can be a valuable time for doctors to rob.

In 2017, the chest pain center took the lead in the layout. Up to now, more than 400 chest pain centers have been established. We expect that 1,000 chest pain centers will be established by the end of 2019. Corresponding POCT and imaging products all have rigid demands and need to repurchase equipment. Consumables.

The chest pain center has clear test requirements and indicators for emergency intensive care. For example, the indicators that require assessment quality are: (V) Troponin, D-dimer, brain natriuretic peptide, blood gas analysis, and other instant test items from blood Time to obtain the report; (6) The proportion of combined detection of D-dimer and troponin.

Take the Guangdong Province charge as an example. The total charge for the three blood test items is approximately 600 yuan (medical insurance). It is calculated based on the establishment of 1,000 chest pain centers. It is assumed that a single center receives 1000-1600 patients, and a single estimate of the incremental central market is roughly estimated. For 6-100 million, while the establishment of other centers, it continues to raise the demand for emergency medical services.

Suppose the establishment of all five major centers (chest centres, stroke centres, trauma centers, critical maternal care centres, critically ill children and neonatal care centres) by 2022, with the exception of the rapid growth of the POCT industry itself, with a further increase of approximately 3.5 billion to 500 million. The amount of space.

In summary, the growth rate of POCT products will benefit from the construction of the five major medical centers that the government will push forward.

The chest pain center that was established in 2017, and other centers that were established in 2018, are expected to complete their layout in 2020-2022. At this stage, we judge that the incremental POCT space will bring strong growth momentum to the market.

Innovation policy support to promote POCT technology upgrade, the industry has room for improvement

High-end manufacturing and innovation are the major trends in the future. The accuracy and repeatability of POCT products have always been the pain point of product application. Therefore, the change and improvement of technology is also an important factor in the future change pattern.

The “Three-Year Action Plan for Enhancing the Core Competitiveness of Manufacturing Industry (2018-2020)” clearly supports the in vitro diagnostic products such as high-throughput gene sequencing instruments, chemiluminescence immunoassay analyzers, new molecular diagnostic instruments, and high-precision real-time inspection systems (POCT). ) And other product upgrades and quality performance.

The promotion of policies and the promotion of competition are the driving forces for the continuous improvement and enhancement of POCT products in the future. The innovation channels introduced in recent years, such as the Green Passage, will accelerate innovation. medical instruments Speed ​​of review.

We take root in the industry, and the product development of the future POCT will inevitably center around some high-tech upgrades, such as microfluidics, micro-droplets, sensors, and chips. The core of this is how to make highly-accurate devices more 'concentrated'. Fast and portable is no longer at the expense of the accuracy of the test results, fast + convenient + accurate, is the direction of global manufacturers work together.